Pear Therapeutics reports $101,640 net loss for August

By Sarah Lizee

Olympia, Wash., Sept. 21 – Pear Therapeutics, Inc. reported a $101,640 net loss for August on zero gross income/sales, according to its monthly operating report filed Wednesday with the U.S. Bankruptcy Court for the District of Delaware.

The cash balance at the end of the month was $205,013.

Boston-based Pear Therapeutics develops and commercializes software-based medicines called prescription digital therapeutics. The company filed bankruptcy on April 7 under Chapter 11 case number 23-10429.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.